Abstract:Cystic fibrosis (CF) is a life‐limiting genetic condition, affecting over 90,000 people worldwide. CF affects several organs in the body, but airway damage has the most profound impact on quality of life (QoL) and survival. Causes of lower airway infection in people with CF are, most notably, Staphylococcus aureus in the early course of the disease and Pseudomonas aeruginosa at a later stage. Macrolide antibiotics, e.g. azithromycin and clarithromycin, are usually taken orally, have a broad spectrum of action against gram‐positive (e.g. S aureus ) and some gram‐negative bacteria (e.g. Haemophilus influenzae ), and may have a modifying role in diseases involving airway infection and inflammation such as CF. They are well‐tolerated and relatively inexpensive, but widespread use has resulted in the emergence of resistant bacteria. This is an updated review. To assess the potential effects of macrolide antibiotics on clinical status in terms of benefit and harm in people with CF. If benefit was demonstrated, we aimed to assess the optimal type, dose and duration of macrolide therapy. We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches, handsearching relevant journals, and abstract books of conference proceedings. We last searched the Group's Cystic Fibrosis Trials Register on 2 November 2022. We last searched the trial registries WHO ICTRP and clinicaltrials.gov on 9 November 2022. We contacted investigators known to work in the field, previous authors and pharmaceutical companies manufacturing macrolide antibiotics for unpublished or follow‐up data, where possible. We included randomised controlled trials of macrolide antibiotics in adults and children with CF. We compared them to: placebo; another class of antibiotic; another macrolide antibiotic; or the same macrolide antibiotic at a different dose or type of administration. Two authors independently extracted data and assessed risk of bias. We assessed the certainty of evidence using GRADE. We included 14 studies (1467 participants) lasting 28 days to 36 months. All the studies assessed azithromycin: 11 compared oral azithromycin to placebo (1167 participants); one compared a high dose to a low dose (47 participants); one compared nebulised to oral azithromycin (45 participants); and one looked at weekly versus daily dose (208 participants). Oral azithromycin versus placebo There is a slight improvement in forced expiratory volume (FEV 1 % predicted) in one second in the azithromycin group at up to six months compared to placebo (mean difference (MD) 3.97, 95% confidence interval (CI) 1.74 to 6.19; high‐certainty evidence), although there is probably no difference at three months, (MD 2.70%, 95% CI ‐0.12 to 5.52), or 12 months (MD ‐0.13, 95% CI ‐4.96 to 4.70). Participants in the azithromycin group are probably at a decreased risk of pulmonary exacerbation with a longer time to exacerbation (hazard ratio (HR) 0.61, 95% CI 0.50 to 0.75; moderate‐certainty evidence). Mild side effects were common, but there was no difference between groups (moderate‐certainty evidence). There is no difference in hospital admissions at six months (odds ratio (OR) 0.61, 95% CI 0.36 to 1.04; high‐certainty evidence), or in new acquisition of P aeruginosa at 12 months (HR 1.00, 95% CI 0.64 to 1.55; moderate‐certainty evidence). High‐dose versus low‐dose azithromycin We are uncertain whether there is any difference in FEV 1 % predicted at six months between the two groups (no data available) or in the rate of exacerbations per child per month (MD ‐0.05 (95% CI ‐0.20 to 0.10)); very low‐certainty evidence for both outcomes. Only children were included in the study and the study did not report on any of our other clinically important outcomes. Nebulised azithromycin versus oral azithromycin We were unable to include any of the data into our analyses and have reported findings directly from the paper; we graded all evidence as being of very low certainty. The authors reported that there was a greater mean change in FEV 1 % predicted at one month in the nebulised azithromycin group (P < 0.001). We are uncertain whether there was a change in P aeruginosa count. Weekly azithromycin versus daily azithromycin There is probably a lower mean change in FEV 1 % predicted at six months in the weekly group compared to the daily group (MD ‐0.70, 95% CI ‐0.95 to ‐0.45) and probably also a longer period of time until first exacerbation in the weekly group (MD 17.30 days, 95% CI 4.32 days to 30.28 days). Gastrointestinal side effects are probably more common in the weekly group and there is likely no difference in admissions to hospital or QoL. We graded all evidence as moderate certainty. Azithromycin therapy i -Abstract Truncated-

A decade of real‐world clinical experience with 8‐week azithromycin–metronidazole combined therapy in paediatric Crohn's disease

Short-Term Efficacy of Exclusive Enteral Nutrition in Pediatric Crohn’s Disease: Practice in China

A prospective randomly controlled clinical trial on azithromycin therapy for induction treatment of children with nephrotic syndrome

Standard‐dose Versus Low‐dose Azathioprine in the Treatment of Crohn's Disease: A Prospective Randomized Study

Discontinuation of Azathioprine could be considered in pediatric patients with Crohn’s disease who have sustained clinical and deep remission

Three Days of Oral Azithromycin Versus Five Days of Oral Clarithromycin in the Treatment of Campylobacter Enterocolitis in Children: A Prospective Study

Efficacy of Azithromycin plus Glucocorticoid Adjuvant Therapy on Serum Inflammatory Factor Levels and Incidence of Adverse Reactions in Children with Mycoplasma Pneumonia

P648 Dietary therapy using a short course of Exclusive Enteral Nutrition followed by the Crohn’s Disease Exclusion Diet in children with mild to severe Crohn’s Disease; maintenance update on the DIETOMICS trial

P919 Crohn’s Disease Exclusion Diet as add-on therapy in refractory pediatric patients

Low dose of azathioprine is effective to induce and maintain remission in active Crohn disease: A prospective observational study.

Formula modifications to the Crohn's disease exclusion diet do not impact therapy success in paediatric Crohn's disease

Repeated and multiple fecal microbiota transplantations plus partial enteral nutrition as the first-line treatment in active pediatric Crohn's disease

Macrolide antibiotics (including azithromycin) for cystic fibrosis

P512 Early proactive therapeutic drug monitoring with ustekinumab therapy in paediatric Crohn's Disease

Long-Term Azithromycin Treatment in Pediatric Primary Ciliary Dyskinesia: A Retrospective Study

[Diagnosis and treatment of Crohn's disease in children: 10 years' clinical experience].

P1207 Microbiome composition determines sustained remission after the Crohn’s Disease Exclusion Diet (CDED) with or without Partial Enteral Nutrition in adults with mild-moderate Crohn’s disease; Results from the CDED-AD Pilot Randomized Controlled Trial

Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn’s disease

STEP-CD study: ustekinumab use in paediatric Crohn's disease—a multicentre retrospective study from paediatric IBD Porto group of ESPGHAN

Minimal impact on the resistome of children in Botswana after azithromycin treatment for acute severe diarrhoeal disease

Efficacy of infliximab after loss of response of/intolerance to adalimumab in pediatric Crohn's disease: A retrospective multicenter cohort study of the "GETAID pédiatrique"